These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 28766537)

  • 1. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
    Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
    Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
    Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
    Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of
    Cheng P; Guan J; Zhou Y; Wang QX; Wang LL; Zhang T; Cheng H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):164-170. PubMed ID: 38387916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New agents-based induction chemotherapy followed by autologous stem cell transplantation and maintenance treatment strategy for multiple myeloma: a single center retrospective study of 300 cases].
    Liu JR; Gu JL; Huang BH; Kuang LF; Chen ML; Zou WY; Zheng D; Wang HH; Xu DR; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1003-1009. PubMed ID: 36709105
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
    Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
    [No Abstract]   [Full Text] [Related]  

  • 6. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.
    Hu B; Thall P; Milton DR; Sasaki K; Bashir Q; Shah N; Patel K; Popat U; Hosing C; Nieto Y; Lin P; Delgado R; Jorgensen J; Manasanch E; Weber D; Thomas S; Orlowski RZ; Champlin R; Qazilbash MH
    Leuk Lymphoma; 2019 Feb; 60(2):442-452. PubMed ID: 30032678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
    Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
    Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of Pre-Transplant CONUT and Post-Transplant MRD on Prognosis of Patients with Multiple Myeloma after Auto-HSCT].
    Xiong YY; Zhou Q; Chen L; Yu W; Zhang HB; Chen JB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):146-154. PubMed ID: 38387913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
    Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
    Shen LJ; Zhuansun SY; Ni BW; Zhang MY; Lu SS; Hua YN; Xiao D; Huang HH; Han XF; Zhong L; Zhong H; Wang T; Hou J
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2861-2867. PubMed ID: 36153871
    [No Abstract]   [Full Text] [Related]  

  • 14. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
    Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
    J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
    Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prognostic significance of minimal residual disease detection after first induction treatment in adult acute lymphoblastic leukemia patients treated with autologous stem cell transplantation].
    Huang ZF; Xu J; Fu MW; Wang TY; Hao M; Liu W; Qiu LG; Zou DH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):105-110. PubMed ID: 30831624
    [No Abstract]   [Full Text] [Related]  

  • 19. [Outcomes of adults with Ph-negative B-cell acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of minimal residual disease].
    Ding Z; Han M; Chen S; Ma Q; Wei J; Pang A; Huang Y; Zhang X; Liang C; Liu X; Yao J; Li G; Cao Y; Feng S; Jiang E
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):587-92. PubMed ID: 26304084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival.
    Pasquini MC; Wallace PK; Logan B; Kaur M; Tario JD; Howard A; Zhang Y; Brunstein C; Efebera Y; Geller N; Giralt S; Hari P; Horowitz MM; Koreth J; Krishnan A; Landau H; Somlo G; Shah N; Stadtmauer E; Vogl DT; Vesole DH; McCarthy PL; Hahn T
    J Clin Oncol; 2024 Aug; 42(23):2757-2768. PubMed ID: 38701390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.